Physician-scientist Scott Armstrong focuses on defining genetic and epigenetic programs that control the extensive self-renewal properties associated with leukemia and other cancers.
Memorial Sloan-Kettering Physician-in-Chief José Baselga studies mechanisms of resistance to targeted therapies and identification of novel therapeutic combinations in solid cancers.
Physician-scientist Emily Cheng focuses on the molecular mechanisms of cell death and their implications in tumorigenesis and cancer therapy, with primary emphasis on lung and kidney cancers.
Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic transcription factors in GIST and other solid tumors.
Physician-scientist James Hsieh focuses on developing novel therapeutics targeting cancer cell proliferation; he also directs Memorial Sloan-Kettering’s translational kidney cancer research program.
Physician-scientist Christopher Park focuses on the identification and characterization of molecular pathways that regulate normal and malignant stem cells in the hematopoietic system.
Physician-scientist Jorge Reis-Filho focuses on the development of a predictive molecular classification for rare types of breast cancer and characterization of intratumor genetic heterogeneity in breast cancers.
Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.
